Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.

Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter

By Lisa Levin

June 6, 9:17 AM

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

BHVN

‘New York Regulators Greenlight Rec Market Entrance Of Six Medical Cannabis Behemoths’ – GreenMarketReport

By Benzinga Newsdesk

December 8, 3:02 PM

https://www.greenmarketreport.com/new-york-regulators-greenlight-rec-market-entrance-of-six-medical-cannabis-behemoths/New York marijuana regulators on Friday gave the formal thumbs up to six of the state's 10 licensed

ACRHF

NantHealth Q2 EPS $(0.10) Misses $(0.09) Estimate, Sales $16.50M Miss $17.01M Estimate

By Bill Haddad

August 4, 5:37 PM

NantHealth (NASDAQ:NH) reported quarterly earnings of $0.10 per share. This is a 225 percent increase over losses of $(0.08) per share from the same period last year. The company reported $16.50 million in sales this quarter. This is a 2.55 percent increase over sales of $16.09 million the same period last year.